Transplant characteristics and complications after transplantation
| Patient outcomes . | ||
|---|---|---|
| . | With single-agent PPX . | No PPX . |
| Number of patients, N | 12 | 12 |
| Graft characteristics, mean cell dose × 106/kg (range) | ||
| CD34+ cells | 7.41 (3.7-11.4) | 6.86 (2.9-12.2) |
| Treg cells | 2.50 (0.7-3.0) | 2.49 (1.7-3.1) |
| Tcon cells | 2.81 (0.7-3.0) | 2.80 (1.7-3.0) |
| Treg purity, % | 93.4 (89.3-96.5) | 91.2 (85.4-97.4) |
| CMV infection status | ||
| CMV-positive recipient, n (%) | 7 (58) | 11 (92) |
| No reactivation, n (%) | 9 (75) | 5 (42) |
| Low-level viremia, n (%) | 1 (8) | 1 (8) |
| Required treatments, n (%) | 2 (17) | 6 (50) |
| EBV | ||
| No reactivation, n (%) | 7 (58) | 3 (25) |
| Low-level viremia, n (%) | 3 (25) | 9 (75) |
| Required treatments, n (%) | 2 (17) | 3 (2 with PTLD, 25) |
| Serious complications, n (%) | ||
| SAE | 1 (8) | 5 (42) |
| SOS | 1 (8) | 1 (8) |
| Relapse | 4 (33) | 1 (8) |
| Death | 3 (25) | 2 (17) |
| cGVHD | 1 (8) | 5 (42) |
| Median follow-up, d (range) | 738 (261-906) | 870 (76-1091) |
| Patient outcomes . | ||
|---|---|---|
| . | With single-agent PPX . | No PPX . |
| Number of patients, N | 12 | 12 |
| Graft characteristics, mean cell dose × 106/kg (range) | ||
| CD34+ cells | 7.41 (3.7-11.4) | 6.86 (2.9-12.2) |
| Treg cells | 2.50 (0.7-3.0) | 2.49 (1.7-3.1) |
| Tcon cells | 2.81 (0.7-3.0) | 2.80 (1.7-3.0) |
| Treg purity, % | 93.4 (89.3-96.5) | 91.2 (85.4-97.4) |
| CMV infection status | ||
| CMV-positive recipient, n (%) | 7 (58) | 11 (92) |
| No reactivation, n (%) | 9 (75) | 5 (42) |
| Low-level viremia, n (%) | 1 (8) | 1 (8) |
| Required treatments, n (%) | 2 (17) | 6 (50) |
| EBV | ||
| No reactivation, n (%) | 7 (58) | 3 (25) |
| Low-level viremia, n (%) | 3 (25) | 9 (75) |
| Required treatments, n (%) | 2 (17) | 3 (2 with PTLD, 25) |
| Serious complications, n (%) | ||
| SAE | 1 (8) | 5 (42) |
| SOS | 1 (8) | 1 (8) |
| Relapse | 4 (33) | 1 (8) |
| Death | 3 (25) | 2 (17) |
| cGVHD | 1 (8) | 5 (42) |
| Median follow-up, d (range) | 738 (261-906) | 870 (76-1091) |
cGVHD, chronic GVHD; SAE, severe adverse event; SOS, sinusoidal obstruction syndrome.